As a highly effective inhibitor targeting MLL, Menin reduced leukemia burden significantly and prolonged survival in in vivo experiments, which indicated that Menin may be effective in treating myeloid leukemia with EVI1high (35, 36). Here, KMT2A is linked to leukemia.